Furthermore, the association between heightened METTL1 expression and unfavorable prognosis indicates its potential as an autonomous risk factor in gliomas, emphasizing its importance in tumorigenesis and resistance to therapies such as temozolomide [210,211]. This evidence concerns the gene METTL1 and central nervous system cancer.